Anixa Biosciences Inc (ANIX)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-03-11

Key Insights

Anixa Biosciences held its 2026 annual meeting of stockholders, with 20.8 million shares present or represented by proxy, representing 62% of the company's outstanding shares.
Shareholders re-elected the four incumbent directors, approved the company's executive compensation in a non-binding advisory vote, and ratified the appointment of Haskell & White LLP as the independent auditor for fiscal year 2026.
The presentation attached to the 8-K filing may be used by the company for future investor meetings, indicating the company's focus on communicating its business and strategies to the investment community.

Quarterly Report Filed: 2026-03-09

Key Insights

The company has been actively conducting research and development, as evidenced by the increases in R&D expenses over the comparable periods.
Anixa Biosciences has been raising additional capital through an at-the-market equity offering, which could provide funding for its ongoing operations and development efforts.
The company has granted stock options and other equity-based awards to its employees and consultants as part of its equity compensation plans, which may dilute existing shareholders.

Current Report Filed: 2026-02-09

Key Insights

Anixa Biosciences reported encouraging patient survival data from its ovarian cancer CAR-T therapy Phase 1 clinical trial, indicating potential efficacy of the treatment.
The company received regulatory approval to escalate the dosage in the clinical trial beyond the original protocol, which could further improve the therapeutic potential of the CAR-T therapy.
The positive clinical trial results and dose escalation approval suggest the company is making progress in developing its novel cancer treatment, which could be a significant milestone for the business.

Insider Trading Filed: 2026-01-29

Key Insights

Insider Arnold M. Baskies, a director at Anixa Biosciences, acquired 10,000 shares of the company's common stock on January 28, 2026 at $3.04 per share, increasing his direct beneficial ownership to 135,000 shares.
This insider purchase suggests Baskies has a positive outlook on the company's future prospects and is willing to invest his own capital, which could be a bullish signal for investors.
The size of the purchase, representing a substantial increase in Baskies' personal stake, indicates he believes the stock is undervalued and has significant upside potential.

Annual Report Filed: 2026-01-12

Key Insights

Anixa Biosciences Inc. is a biotechnology company focused on developing innovative cancer and infectious disease therapies. The company's fiscal year 2025 ended on October 31, 2025.
Anixa's research and development expenses increased from $X in fiscal year 2024 to $Y in fiscal year 2025, indicating continued investment in its pipeline.
The company's Series A Convertible Preferred Stock holdings have remained consistent at Z shares from fiscal year 2024 to 2025, suggesting stability in its capital structure.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.